Clinical trial
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With…
NCT00061672 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00061672 |
|---|---|
| Title | Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma |
| Official title | A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin, Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | ABT-510 - Thrombospondin-1 Mimetic |
| Enrollment | 67 |
| Start date | Apr 1, 2003 |
| First posted | Jun 4, 2003 |
| Last update posted | Aug 15, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: